Entity Common Stock, Shares Outstanding of Aclaris Therapeutics, Inc. from 17 Nov 2015 to 30 Jan 2026

Taxonomy & unit
dei: shares
Description
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
Summary
Aclaris Therapeutics, Inc. quarterly Entity Common Stock, Shares Outstanding in shares history and change rate from 17 Nov 2015 to 30 Jan 2026.
  • Aclaris Therapeutics, Inc. Entity Common Stock, Shares Outstanding for the quarter ending 30 Jan 2026 was 120,595,189, a 12% increase year-over-year.
Source SEC data
View on sec.gov
Entity Common Stock, Shares Outstanding, Quarterly (shares)
Entity Common Stock, Shares Outstanding, YoY Quarterly Change (%)

Aclaris Therapeutics, Inc. Quarterly Entity Common Stock, Shares Outstanding (shares)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 120,595,189 +12,676,368 +12% 30 Jan 2026 10-K 26 Feb 2026 2025 FY
Q3 2025 108,345,239 +36,914,297 +52% 31 Oct 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 108,332,218 +36,987,661 +52% 31 Jul 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 108,281,239 +37,016,453 +52% 30 Apr 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 107,918,821 +36,993,779 +52% 31 Jan 2025 10-K 27 Feb 2025 2024 FY
Q3 2024 71,430,942 +594,748 +0.84% 31 Oct 2024 10-Q 06 Nov 2024 2024 Q3
Q2 2024 71,344,557 +549,915 +0.78% 31 Jul 2024 10-Q 07 Aug 2024 2024 Q2
Q1 2024 71,264,786 +585,391 +0.83% 30 Apr 2024 10-Q 07 May 2024 2024 Q1
Q4 2023 70,925,042 +4,232,078 +6.3% 31 Jan 2024 10-K 27 Feb 2024 2023 FY
Q3 2023 70,836,194 +4,153,003 +6.2% 31 Oct 2023 10-Q 06 Nov 2023 2023 Q3
Q2 2023 70,794,642 +4,122,892 +6.2% 31 Jul 2023 10-Q 07 Aug 2023 2023 Q2
Q1 2023 70,679,395 +4,097,492 +6.2% 28 Apr 2023 10-Q 08 May 2023 2023 Q1
Q4 2022 66,692,964 +5,417,931 +8.8% 31 Jan 2023 10-K 23 Feb 2023 2022 FY
Q3 2022 66,683,191 +5,455,858 +8.9% 31 Oct 2022 10-Q 08 Nov 2022 2022 Q3
Q2 2022 66,671,750 +5,456,043 +8.9% 29 Jul 2022 10-Q 03 Aug 2022 2022 Q2
Q1 2022 66,581,903 +14,474,548 +28% 29 Apr 2022 10-Q 10 May 2022 2022 Q1
Q4 2021 61,275,033 +9,470,775 +18% 31 Jan 2022 10-K 24 Feb 2022 2021 FY
Q3 2021 61,227,333 +18,308,042 +43% 29 Oct 2021 10-Q 02 Nov 2021 2021 Q3
Q2 2021 61,215,707 +18,492,927 +43% 30 Jul 2021 10-Q 05 Aug 2021 2021 Q2
Q1 2021 52,107,355 +10,241,010 +24% 30 Apr 2021 10-Q 07 May 2021 2021 Q1
Q4 2020 51,804,258 31 Jan 2021 10-K 25 Feb 2021 2020 FY
Q3 2020 42,919,291 +1,530,859 +3.7% 31 Oct 2020 10-Q 04 Nov 2020 2020 Q3
Q2 2020 42,722,780 +1,354,556 +3.3% 06 Aug 2020 10-Q 07 Aug 2020 2020 Q2
Q1 2020 41,866,345 +596,702 +1.4% 01 May 2020 10-Q 07 May 2020 2020 Q1
Q3 2019 41,388,432 +452,241 +1.1% 07 Nov 2019 10-Q 07 Nov 2019 2019 Q3
Q2 2019 41,368,224 +10,387,561 +34% 05 Aug 2019 10-Q 08 Aug 2019 2019 Q2
Q1 2019 41,269,643 +10,368,151 +34% 15 Mar 2019 10-K 18 Mar 2019 2018 FY
Q3 2018 40,936,191 +10,101,512 +33% 05 Nov 2018 10-Q 06 Nov 2018 2018 Q3
Q2 2018 30,980,663 +4,244,146 +16% 02 Aug 2018 10-Q 03 Aug 2018 2018 Q2
Q1 2018 30,901,492 +4,812,626 +18% 09 Mar 2018 10-K 12 Mar 2018 2017 FY
Q3 2017 30,834,679 +9,401,772 +44% 06 Nov 2017 10-Q 07 Nov 2017 2017 Q3
Q2 2017 26,736,517 +5,321,120 +25% 07 Aug 2017 10-Q 08 Aug 2017 2017 Q2
Q1 2017 26,088,866 +5,931,363 +29% 14 Mar 2017 10-K 15 Mar 2017 2016 FY
Q3 2016 21,432,907 02 Nov 2016 10-Q 03 Nov 2016 2016 Q3
Q2 2016 21,415,397 10 Aug 2016 10-Q 11 Aug 2016 2016 Q2
Q1 2016 20,157,503 23 Mar 2016 10-K 23 Mar 2016 2015 FY
Q4 2015 20,157,503 17 Nov 2015 10-Q 03 Dec 2015 2015 Q3
* An asterisk sign (*) next to the value indicates that the value is likely invalid.